Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-4 is a potent dual-target inhibitor of CYP51 and PD-L1, demonstrating IC50 values of 0.17 μM and 0.021 μM, respectively. This compound exhibits significant antifungal activity and is effective against drug-resistant fungal strains in vitro. CYP51/PD-L1-IN-4 is suitable for research applications focused on fungal infections and the interplay between fungal pathogens and immune checkpoint regulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-22 is a small-molecule inhibitor specifically targeting the PD-1/PD-L1 protein-protein interaction. With an IC50 value of 0.732 μM, it effectively disrupts this pathway, making it a valuable tool in cancer, infectious disease, and autoimmune disease research. Its ability to modulate immune responses positions PD-1/PD-L1-IN-22 as a significant compound for therapeutic development in immunooncology and related fields. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-18 is a small-molecule inhibitor that specifically targets the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 of 1.054 μM. This compound effectively blocks PD-1/PD-L1 signaling, facilitating enhanced T-cell activation and antitumor responses. It is valuable for research applications focused on immunotherapy and cancer treatment strategies. -
PD-L1 Inhibitor
PD-L1-IN-8 is a selective PD-L1 inhibitor with an IC50 of 0.89 nM. It demonstrates low inhibition of cytochrome P450 enzymes and minimal hERG activity, indicating a favorable safety profile. This compound is specifically useful in the investigation of PD-L1 mediated immune evasion in colon cancer research, contributing to the understanding of tumor-immune system interactions. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-25 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 16.17 nM. This compound effectively enhances T cell antitumor immunity in peripheral blood mononuclear cells (PBMCs). PD-1/PD-L1-IN-25 is instrumental for cancer research, particularly in studies focused on immunotherapy and tumor microenvironment modulation. -
PD-L1/CD-73 Inhibitor
PD-L1/CD-73-IN-1 is a potent inhibitor of PD-L1 and CD73, exhibiting IC50 values of 6 nM and 0.773 μM, respectively. This compound demonstrates significant biological activity by inhibiting tumor cell growth both in vitro and in vivo. It is an essential tool for research applications focused on immune modulation and cancer therapy. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-58 is a selective inhibitor of the PD-1/PD-L1 pathway, demonstrating a dissociation constant (KD) of 77.60 nM for PD-L1 in comparison to PD-1. This compound exhibits oral bioactivity and is particularly relevant for investigations into immune modulation and potential therapeutic strategies against influenza A virus. Its mechanism of action makes it a valuable tool for research aimed at understanding and manipulating immune responses in various disease contexts. -
PD-1/PD-L1 Inhibitor
LH1306 is a C2-symmetric inhibitor specifically targeting the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 value of 25 nM. This compound is pivotal for studies investigating immune checkpoint blockade and its potential applications in anti-tumor research. By modulating immune responses, LH1306 serves as a valuable tool for exploring therapeutic strategies in cancer immunotherapy. -
Inflammatory Cytokine Inhibitor
JTE-607 is a selective inhibitor targeting the Cleavage and Polyadenylation Specificity Factor 3 (CPSF3), demonstrating potent suppression of inflammatory cytokine synthesis. This compound effectively reduces the production of key inflammatory cytokines, including TNF-α, IL-1β, IL-6, IL-8, and IL-10 in LPS-stimulated human peripheral blood mononuclear cells (PBMCs) with IC50 values of 11, 5.9, 8.8, 7.3, and 9.1 nM, respectively. JTE-607 is utilized in research applications focused on understanding and mitigating inflammatory responses and endotoxin shock. -
IL-17A Inhibitor
LY3509754 is a potent IL-17A inhibitor, demonstrating IC50 values of less than 9.45 nM in alphaLISA assays and 9.3 nM in HT-29 cell assays. This compound's selective inhibition of IL-17A makes it a valuable tool for investigating the role of IL-17A in inflammatory diseases and immune responses. Its use in research applications can help elucidate the therapeutic potential for conditions associated with IL-17A signaling. -
IL6/STAT3 Inhibitor
Angoline is a selective inhibitor of the IL6/STAT3 signaling pathway, demonstrating an IC50 of 11.56 μM. It effectively inhibits the phosphorylation of STAT3, leading to reduced expression of target genes associated with cancer progression. This compound is valuable for research applications focused on cancer biology and the modulation of inflammatory responses. -
Cyclophilin Inhibitor
Rencofilstat (CRV431) is a potent pan-cyclophilin inhibitor that targets multiple cyclophilins with IC50 values of 2.5 nM for Cyp A, 3.1 nM for Cyp B, 2.8 nM for Cyp D, and 7.3 nM for Cyp G. This compound is effective in reducing fibrosis and tumor growth in chronic liver disease models. Rencofilstat is suitable for research applications related to nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma, and liver diseases induced by viral hepatitis. -
Nrf2 inhibitory protein Keap-1 Activator
KMS99220 is a potent activator of the Nrf2 inhibitory protein Keap-1, capable of crossing the blood-brain barrier. This compound enhances AMPK activity and activates the Nrf2 signaling pathway, leading to decreased phosphorylation of IκB, reduced translocation of NFκB, and modulation of MAPK pathways. KMS99220 promotes the expression of neuroprotective genes, including HO-1 and NQO1, and exhibits anti-inflammatory properties by inhibiting iNOS and IL-1β production. Its application in research focuses on understanding neurodegenerative diseases like Parkinson's disease, particularly its effects on dopaminergic neuron preservation and associated motor dysfunction. -
IL-2/IL-2Rα Inhibitor
SP4206 is an inhibitor of the IL-2/IL-2Rα interaction, exhibiting high-affinity binding to IL-2 with a dissociation constant (Kd) of 70 nM. By effectively blocking the interaction with its natural receptor IL-2Rα, which has a Kd of 10 nM, SP4206 has significant potential for modulating immune responses. This compound is valuable for research applications focused on autoimmune diseases, cancer immunotherapy, and enhancing our understanding of IL-2-mediated signaling pathways. -
IL-18 Inhibitor
NSC80734 is an IL-18 inhibitor that effectively disrupts the binding of human IL-18 to ectromelia virus IL-18 binding protein (IL-18BP). This compound inhibits the IL-18-mediated production of interferon-gamma (IFN-γ), making it a valuable tool for studying the role of IL-18 in inflammatory processes and immune responses. NSC80734 is applicable in research focusing on cytokine signaling and related biological pathways. -
IL-17C/IL-17RE Interaction Inhibitor
Lib2-1 is a macrocyclic peptide that functions as an inhibitor of the IL-17C/IL-17RE interaction. This compound demonstrates significant potential in modulating inflammatory responses, making it a valuable tool in the study of autoimmune and inflammatory diseases. Researchers can utilize Lib2-1 to investigate the underlying mechanisms of IL-17C signaling and its implications in various pathological conditions. -
TYK2 Inhibitor
QL-1200186 is a selective, orally active allosteric inhibitor specifically targeting the pseudokinase domain JH2 of tyrosine kinase TYK2, exhibiting an IC50 of 0.06 nM with 164-fold selectivity over TYK1 JH2 (IC50 = 9.85 nM). By stabilizing the TYK2 JH2 conformation, QL-1200186 inhibits the activity of the JH1 catalytic domain and disrupts the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. This compound effectively reduces the production of Th1/Th17-related cytokines and has shown promise in alleviating skin inflammation in Imiquimod-induced psoriasis models, making it relevant for the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE). -
IL-18 Inhibitor
NSC61610 is an inhibitor of interleukin-18 (IL-18) that disrupts the binding of human IL-18 to the ectromelia virus IL-18 binding protein (IL-18BP). It effectively inhibits the formation of the hIL-18:ectvIL-18BP complex, demonstrating an IC50 of approximately 6 µM. This compound is valuable for research applications involving inflammatory responses and the study of viral interactions with host immune mechanisms. -
IL-1 Inhibitor
Lys-D-Pro-Thr is an IL-1β analogue, specifically targeting the positions 193-195 of the IL-1β protein. It acts as a potent inhibitor of IL-1, playing a critical role in regulating inflammatory responses. This reagent is valuable for research applications focused on inflammatory pathways, autoimmune diseases, and the modulation of cytokine signaling. -
IL-17A Inhibitor
Navepdekinra is a potent inhibitor of interleukin-17A (IL-17A), with an IC50 of 10.81 nM. By disrupting the interaction between IL-17A and its receptor, Navepdekinra effectively suppresses downstream pro-inflammatory signaling pathways. This compound has demonstrated efficacy in reducing arthritis symptoms in a collagen-induced arthritis rat model and is applicable to research in psoriasis, psoriatic arthritis, and ankylosing spondylitis. -
CD47-SIRPα Signalling Inhibitor
RS17 is a CD47-SIRPα signaling inhibitor that disrupts the interaction between CD47 and its ligand, SIRPα, on macrophage surfaces. By binding to CD47, RS17 prevents the transmission of signals that enable selective phagocytosis, thereby promoting the recognition and clearance of tumor cells by macrophages. This peptide is valuable for researching anti-tumor responses and mechanisms of immune evasion in cancer. -
SIK Inhibitor
PF-07899895 is a selective SIK inhibitor, demonstrating potent activity with IC50 values of 1.2 nM, 0.9 nM, and 1.8 nM against SIK1, SIK2, and SIK3, respectively. This compound effectively modulates the production of the anti-inflammatory cytokine IL-10 in immune cells. PF-07899895 is highly relevant for research into inflammatory diseases and understanding immunological responses. -
IL-23R Inhibitor
IL-23R inhibitor peptide-1 is a potent interleukin-23 receptor inhibitor with an IC50 of 0.0069 μM. It is designed to modulate the signaling pathway of IL-23, which plays a critical role in the pathogenesis of various autoimmune diseases. This reagent is suitable for research applications focused on inflammatory responses and therapeutic strategies targeting IL-23 signaling. -
IL-2 Inhibitor
IL-2-IN-1 is a potent inhibitor of interleukin-2 (IL-2), exhibiting an IC50 value of 1978 nM. It demonstrates significant antiproliferative activity, making it a valuable tool for research in immune modulation and cytokine signaling. This compound is ideal for studies focused on T cell regulation and potential therapeutic applications in autoimmune diseases and cancers linked to IL-2 signaling. -
STING Inhibitor
STING-IN-11 is a potent STING inhibitor with an IC50 of 37.8 nM. By blocking the palmitoylation of the STING protein, it effectively inhibits STING-mediated downstream signaling and associated inflammatory pathways. This compound demonstrates favorable in vivo safety, making it an excellent candidate for research into STING-related inflammatory and autoimmune diseases. -
IL-20/PRINS Inhibitor
Abacavir hydroxyacetate is an orally active inhibitor of IL-20 and PRINS. This compound demonstrates significant immune modulation, effectively reducing the proliferation rate of skin cells in psoriasis. It serves as a valuable tool for investigating inflammatory skin disorders and potential therapeutic strategies in related research applications. -
IL-1β Inhibitor
IL-1β-IN-2 is a potent inhibitor of interleukin-1 beta (IL-1β), a key mediator in inflammatory processes. This cannabigerol derivative exhibits significant anti-inflammatory and analgesic effects, making it a valuable tool for research into conditions driven by IL-1β signaling. IL-1β-IN-2 is suitable for studies focused on inflammatory diseases and pain management, aiding in the understanding and development of therapeutic strategies targeting IL-1β. -
IL-1β Inhibitor
IL-1β-IN-1 is a selective inhibitor of interleukin-1 beta (IL-1β), a key cytokine involved in inflammatory processes. This compound demonstrates significant anti-inflammatory and analgesic effects, making it a valuable tool in research focused on chronic inflammatory conditions and pain management. Its potency and specificity for IL-1β allow for detailed studies on its biological roles and therapeutic applications. -
IL-17 Inhibitor
IL-17-IN-2 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.4 μM, as demonstrated in both HTRF and NHK assays. This compound effectively disrupts IL-17 signaling, making it valuable for research related to inflammatory diseases and immune response modulation. Its significant biological activity allows for exploration in therapeutic contexts targeting IL-17-mediated pathways. -
IL-2 Antibody Inhibitor
Balekafusp alfa is an IgG1K human antibody specifically targeting interleukin-2 (IL-2). It exhibits anti-tumor activity, making it a valuable tool for cancer research and therapeutic studies. This reagent can aid in investigating the immunological mechanisms of IL-2 and its role in tumor progression. Additionally, researchers can utilize it to explore potential applications in immunotherapy and the modulation of immune responses. -
IL-17 Inhibitor
IL-17-IN-5 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.1 μM. This compound is designed for research applications related to inflammatory diseases, facilitating the study of IL-17's role in various pathophysiological processes. IL-17-IN-5 can aid in the development of therapeutic strategies targeting IL-17 signaling pathways. -
IL-1 Inhibitor
Triptoquinone B is a sesquiterpene alkaloid that functions as an interleukin-1 inhibitor. It exhibits significant inhibitory effects on the release of interleukin 1α and 1β from human peripheral mononuclear cells, making it a valuable reagent for studies focused on inflammatory processes and cytokine signaling. This compound is useful for research into immune responses and related therapeutic applications. -
CSF1R/Mer/Axl Inhibitor
Adrixetinib is a potent triple inhibitor targeting CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM respectively. This compound serves as an effective immune modulator by remodeling the tumor microenvironment, enhancing the presence of M1 macrophages and CD8⁺ T cells while reducing M2 macrophages and myeloid-derived suppressor cells (MDSCs). Additionally, Adrixetinib increases the expression of MHC class I and E-cadherin in tumor cells, demonstrating significant antitumor efficacy in syngeneic mouse models. It is relevant for research involving breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma. -
CD44-Hyaluronan Inhibitor
IGFBP-3 peptide is an 18-amino acid fragment of insulin-like growth factor binding protein-3, known to inhibit the interaction between CD44 and hyaluronan. This peptide effectively binds to Humanin and hyaluronan, thereby blocking their functional interactions. IGFBP-3 peptide serves as a useful tool for researching CD44-related signaling pathways and its role in cellular adhesion and migration. -
COX Inhibitor
(±)-Aiphanol is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-1 (IC50 = 1.9 μM) and COX-2 (IC50 = 9.9 μM). This compound displays significant anti-inflammatory properties and further inhibits vascular endothelial growth factor receptor 2 (VEGFR2) with an IC50 of 0.92 μM. By impeding both COX-2 and VEGFR2 pathways, (±)-Aiphanol effectively blocks angiogenesis and induces apoptosis, making it a valuable tool in the study of inflammatory diseases and cancer research. The compound demonstrates oral bioactivity, enhancing its potential for in vivo applications. -
Keap1-Nrf2 Inhibitor
Keap1-Nrf2-IN-11 is a potent inhibitor of the Keap1-Nrf2 interaction, exhibiting a KD2 value of 0.21 nM. This compound effectively reduces the production of reactive oxygen species (ROS) and nitric oxide (NO), as well as downregulating the expression of tumor necrosis factor-alpha (TNF-α). By promoting Nrf2 nuclear translocation, Keap1-Nrf2-IN-11 demonstrates significant anti-inflammatory properties, making it a valuable tool for research in inflammation-related pathways. -
Complement Inhibitor
3-Phenoxybenzaldehyde is a compound identified as a complement inhibitor, exhibiting weak inhibition of the classical pathway of the complement system. This compound demonstrates hemolytic activity, making it relevant for studies related to immune response modulation and complement pathway research. Its applications extend to investigations in autoimmune diseases and therapies targeting complement-mediated cytotoxicity. -
C5 Complement Inhibitor
Avacincaptad pegol is a pegylated RNA aptamer that selectively inhibits complement component C5. By preventing the cleavage of C5 into pro-inflammatory fragments C5a and C5b, this compound mitigates inflammatory cell recruitment and reduces retinal cell damage. Avacincaptad pegol has demonstrated potential in slowing the progression of geographic atrophy (GA) lesions and decreasing the risk of vision loss, making it a valuable tool for research involving age-related macular degeneration (AMD). -
Complement System Inhibitor
Factor B-IN-1 is an inhibitor of Factor B, targeting the complement system to modulate its activity. This compound demonstrates significant inhibition of the alternative pathway of complement activation, making it a valuable tool for studying complement-mediated diseases and immune responses. Factor B-IN-1 is suitable for use in research applications focused on therapeutic interventions and the development of complement-targeted therapies. -
Complement Factor D Inhibitor
Complement Factor D-IN-2 is an inhibitor targeting complement factor D, effectively interrupting the complement cascade at a critical juncture within the alternative complement pathway. By inhibiting factor D, this compound presents valuable opportunities for investigating the role of complement activation in autoimmune diseases. Researchers can utilize Complement Factor D-IN-2 to explore therapeutic strategies aimed at modulating immune responses and mitigating the progression of complement-mediated pathologies. -
Complement Factor D Inhibitor
Refinicopan is a selective inhibitor of complement factor D, demonstrating an IC50 of 10 nM. This compound effectively inhibits rabbit erythrocyte hemolysis with an IC50 of 41 nM, indicating its capacity to modulate complement-mediated processes. Refinicopan's favorable pharmacokinetic and pharmacodynamic properties make it a valuable tool for investigating complement-related disorders and potential therapeutic interventions. -
Complement Protein C5 Inhibitor
Vensobafusp alfa is a fusion protein that targets complement protein C5, functioning as a potent inhibitor. It combines an IgG4 monoclonal antibody directed against C5 with the complement factor H 1-5 domain, demonstrating significant anti-inflammatory and immunomodulatory properties. This reagent is applicable in the study of complement-mediated pathologies and therapeutic strategies targeting inflammatory conditions. -
Complement System Inhibitor
Bisphenol A bissulfate disodium is a complement system inhibitor with a significant role in modulating immune responses. This compound exhibits complement-inhibiting activity, demonstrating an IC50 value of 247 μM. It is utilized in research applications aimed at understanding the complement pathway and its implications in various diseases, making it a valuable tool in immunological studies. -
Complement inhibitor
Bisphenol S disulfate disodium is a complement inhibitor that exhibits a half-maximal inhibitory concentration (IC50) of 660 μM. This compound is utilized in research applications aiming to explore complement-mediated pathways and their roles in various biological processes and diseases. Its ability to modulate complement activity makes it a valuable tool for studies involving immune response and inflammation. -
TLR7/8 Inhibitor
Enpatoran is a potent and orally active dual inhibitor of Toll-like receptors 7 and 8, exhibiting IC50 values of 11.1 nM and 24.1 nM, respectively, in HEK293 cells. This compound is selective, showing no activity against TLR3, TLR4, or TLR9. Enpatoran effectively blocks both synthetic and natural RNA ligands, demonstrating excellent pharmacokinetic properties in vivo. It is a valuable tool for research focused on modulating innate and adaptive immune responses related to autoimmunity. -
TLR3 Inhibitor
CU-CPT 4a is a selective inhibitor of TLR3 signaling, effectively blocking the downstream pathways activated by the TLR3/dsRNA complex. This compound suppresses the production of pro-inflammatory cytokines, including TNF-α and IL-1β, making it a valuable tool for research into immune responses and inflammation. CU-CPT 4a is suitable for studies focused on modulating TLR3-related signaling pathways in various disease models. -
SARM1 Activator/CD38 Inhibitor
Sulfo-ara-F-NMN is a selective SARM1 activator and CD38 inhibitor, functioning as a mimetic of nicotinamide mononucleotide (NMN). It effectively activates SARM1 while inhibiting CD38, with an IC50 of approximately 10 μM. This compound is valuable for research applications focused on the modulation of intracellular cyclic ADP-ribose (cADPR) production and the exploration of pathways involving SARM1 and CD38 in cellular signaling. -
TLR7/TLR9 Inhibitor
AT791 is a potent inhibitor of Toll-like receptors 7 and 9 (TLR7/TLR9), demonstrating strong oral bioavailability. This compound effectively blocks TLR7 and TLR9 signaling pathways in a range of human and murine cell types, as well as inhibiting DNA-TLR9 interactions in vitro. AT791 is applicable in research focused on immune modulation and the characterization of TLR-mediated signaling. -
TLR3/7/9 Inhibitor
ODN 2088 is a potent inhibitor of Toll-like receptors 3, 7, and 9 (TLR3, TLR7, TLR9), demonstrating a strong capacity to modulate immune responses. This compound effectively suppresses the release of key pro-inflammatory cytokines, including interferon-alpha (IFN-α) and interleukin-6 (IL-6), without exhibiting cytotoxic effects. ODN 2088 is valuable for research applications focused on understanding TLR-mediated signaling pathways and their roles in various immune-related conditions. -
Toll-like Receptor (TLR) Inhibitor
Okanin is a potent Toll-like Receptor (TLR) inhibitor derived from the flowering plant Coreopsis tinctoria. It exhibits significant biological activity by attenuating lipopolysaccharide (LPS)-induced microglial activation via the inhibition of the TLR4/NF-κB signaling pathway. This compound is useful for research applications focusing on neuroinflammation and the modulation of immune responses in microglial cells.
